These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25378522)

  • 1. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?
    Innes H; Goldberg D; Dillon J; Hutchinson SJ
    Gut; 2015 Nov; 64(11):1800-9. PubMed ID: 25378522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C: a changing epidemic.
    Wandeler G; Dufour JF; Bruggmann P; Rauch A
    Swiss Med Wkly; 2015; 145():w14093. PubMed ID: 25658972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland.
    McDonald SA; Hutchinson SJ; Palmateer NE; Allen E; Cameron SO; Goldberg DJ; Taylor A
    J Hepatol; 2013 Mar; 58(3):460-6. PubMed ID: 23149064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).
    Dore GJ; Ward J; Thursz M
    J Viral Hepat; 2014 May; 21 Suppl 1():1-4. PubMed ID: 24713003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
    Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ
    J Hepatol; 2015 Feb; 62(2):269-77. PubMed ID: 25200903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care.
    Fragomeli V; Weltman M
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 2():6-11. PubMed ID: 25641224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States.
    Ward JW
    Clin Liver Dis; 2013 Feb; 17(1):1-11. PubMed ID: 23177279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan.
    McDonald SA; Hutchinson SJ; Innes HA; Allen S; Bramley P; Bhattacharyya D; Carman W; Dillon JF; Fox R; Fraser A; Goldberg DJ; Kennedy N; Mills PR; Morris J; Stanley AJ; Wilks D; Hayes PC
    J Viral Hepat; 2014 May; 21(5):366-76. PubMed ID: 24716639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model.
    Innes H; Goldberg D; Dusheiko G; Hayes P; Mills PR; Dillon JF; Aspinall E; Barclay ST; Hutchinson SJ
    J Hepatol; 2014 Jun; 60(6):1118-26. PubMed ID: 24509410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can hepatitis C virus infection be eradicated in people who inject drugs?
    Grebely J; Dore GJ
    Antiviral Res; 2014 Apr; 104():62-72. PubMed ID: 24468275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C: What lies ahead and can we afford it?
    Howie H; Hutchinson SJ
    J Viral Hepat; 2004 Sep; 11 Suppl 1():28-33. PubMed ID: 15357861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
    Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.
    Buti M; San Miguel R; Brosa M; Cabasés JM; Medina M; Angel Casado M; Fosbrook L; Esteban R
    J Hepatol; 2005 May; 42(5):639-45. PubMed ID: 15826711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projecting future complications of chronic hepatitis C in the United States.
    Davis GL; Albright JE; Cook SF; Rosenberg DM
    Liver Transpl; 2003 Apr; 9(4):331-8. PubMed ID: 12682882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and clinical aspects on hepatitis C.
    Higuchi M; Tanaka E; Kiyosawa K
    Jpn J Infect Dis; 2002 Jun; 55(3):69-77. PubMed ID: 12195046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and control of hepatitis C in rhode island.
    Alexander-Scott NE; Lemire A; Larson HE; Bandy U
    R I Med J (2013); 2014 Jul; 97(7):25-8. PubMed ID: 24983017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.